Lyanne Harrison, an analyst from Bank of America Securities, maintained the Buy rating on Resmed (RMD – Research Report). The associated price target remains the same with $280.00.
Lyanne Harrison’s rating is based on Resmed’s strong financial performance in the third quarter of 2025, where the company reported revenues that were largely in line with expectations. The gross margin improved significantly due to efficiencies in manufacturing and logistics, as well as a favorable product mix, despite some negative impacts from foreign currency movements. Additionally, Resmed’s mask sales slightly exceeded consensus expectations, and its Software as a Service (SaaS) segment achieved double-digit growth, aligning with market predictions.
Harrison also considers the potential positive impact from peer recalls and the anticipated benefits from GLP-1 related developments as supportive factors for Resmed’s future performance. These elements, combined with the company’s strategic initiatives and market position, contribute to the Buy rating, indicating confidence in Resmed’s ability to deliver value to shareholders.